Xponance, Inc. Taysha Gene Therapies, Inc. Transaction History
Xponance, Inc.
- $10.7 Billion
- Q4 2024
A detailed history of Xponance, Inc. transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Xponance, Inc. holds 11,925 shares of TSHA stock, worth $19,199. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,925
Previous 10,869
9.72%
Holding current value
$19,199
Previous $21,000
4.76%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TSHA
# of Institutions
130Shares Held
151MCall Options Held
48KPut Options Held
7.8K-
Avoro Capital Advisors LLC New York, NY20MShares$32.2 Million0.5% of portfolio
-
Morgan Stanley New York, NY17.6MShares$28.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$18.9 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$17.5 Million0.3% of portfolio
-
Octagon Capital Advisors LP New York, NY10.5MShares$16.8 Million4.03% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $77.9M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...